Discovery Life Sciences’ Post

Multiple studies associate an HPV-positive status with an improved prognosis¹ for head and neck cancer (HNSCC) patients. Our data shows that 41% of HNSCC patients tested at NeoGenomics were HPV-positive. Data plays a vital role in precision oncology. To learn more about how NeoGenomics has the scientific expertise and innovation to support pharma companies, we invite you to visit: https://lnkd.in/gHc2NcSQ 1: Aggarwal N, Yadav J, Thakur K, Bibban R, Chhokar A, Tripathi T, Bhat A, Singh T, Jadli M, Singh U, Kashyap MK, Bharti AC. Human Papillomavirus Infection in Head and Neck Squamous Cell Carcinomas: Transcriptional Triggers and Changed Disease Patterns. Front Cell Infect Microbiol. 2020 Dec 2;10:537650.

Review Article, The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor-positive, HER2 non-amplified (HR+HER2−) breast cancer. These agents can also be administered as adjuvant therapy to patients with higher-risk early stage disease. Nonetheless, the clinical success of these agents has created several challenges, such as how to address acquired resistance, identifying which patients are most likely to benefit from therapy prior to treatment, and understanding the optimal timing of administration and sequencing of these agents. In this Review, we describe the rationale for targeting CDK4/6 in patients with breast cancer, including a summary of updated clinical evidence and how this should inform clinical practice. https://lnkd.in/g46-tWgq

Today is a big day for Remedy Plan: our first American Society of Hematology appearance! This morning our founder and CEO Gregory Crimmins shared new data during an oral presentation at the meeting. Greg shared data on RPT1G, a small molecule hyperbolic NAMPT inhibitor with a unique, first-in-class mechanism of action. NAMPT dysregulation is responsible for more than 20 diseases, but efforts to target NAMPT to date have been hampered by on-target toxicities. That all changes with Remedy Plan’s RPT1G!  Preclinical and animal studies presented today revealed that RPT1G is efficacious in acute leukemia, lymphoma, and solid tumor models, selectively killing cancer cells. Importantly, RPT1G was thousands-fold better tolerated by healthy cells, without the severe on-target toxicities seen with previous NAMPT inhibitors. Read more here: https://lnkd.in/gqvBcKqB

🔬 **Elevate Cancer Diagnostics with BioGenex’s PRAME Antibody** 🔬 BioGenex is transforming cancer diagnostics with our PRAME antibody, a key biomarker for skin tumors and various malignancies including melanoma, lung, breast, and renal cancers. 🧬 **Why PRAME?** - Essential for assessing metastasis risk. - Broad application across numerous cancers. - Minimal expression in normal tissues. 🔍 **Our Offering** We provide ready-to-use and concentrated Skin & Melanoma Tumor Panel Markers for both manual and automated systems, crucial for clinical diagnostics and drug discovery. 🌐 **Advance with Us** Explore the potential of our PRAME antibody and join us in refining cancer diagnostics for better treatment outcomes. Learn More: https://hubs.la/Q02mbT7Q0 #CancerDiagnostics #PRAME #BioGenex #OncologyInnovation ---

New insights about kidney cancer biomarkers: "The analysis of T-cell receptors within the blood and tumor showed that sunitinib led to higher T-cell counts associated with longer progression-free survival, while avelumab plus axitinib resulted in greater changes in T-cell receptor repertoire and higher clonality. In the tumor, higher T cells were associated with better progression-free survival with immune therapy" Which patients benefit most from TKI vs IO/TKI"? More information to come in renal cancer. So there's more than IMDC risk criteria??

#MensHealthMonth is a time to reflect on the importance of regular screenings, especially when it comes to prostate cancer – the fifth leading cause of cancer deaths among men globally. The AstraZeneca GU/GYN Oncology team is dedicated to providing resources and educating men who are at a higher risk for prostate cancer due to factors such as age, exposure, or family history. Discussing the potential benefits of prostate cancer screening can empower informed decisions, and potentially save lives.   I encourage you to take the opportunity this Men’s Health Month to learn more about what regular screenings are appropriate for yourself or a loved one, including those for prostate cancer. If you’ve been diagnosed with prostate cancer, I urge you to talk to your healthcare team about BRCA mutation testing, which can open doors to potential treatment options. Information on the importance of BRCA testing in prostate cancer can be found here: https://lnkd.in/eAXbrp8g

ICYMI: A recent study presented at #AACR24 and published in JAMA by Feng et al. explored an important question: Can late-stage cancer incidence serve as a surrogate for survival in cancer screening? The answer? As varied as the tumor types themselves. Dr. Peter Bach's accompanying editorial sheds light on the implications for multi-cancer "liquid biopsy" screening. Beyond The Numbers: While the specific findings matter, the study's intent is crucial - to evaluate if new measures can accelerate the clinical utility of new screening technologies. Parallel Insights: The study's implications reach beyond screening. Consider the parallels to surrogate endpoints in cancer therapeutics. For those following #ASCO24, I would revisit https://lnkd.in/gJ632cst. It's a great refresher on how to contextualize the new data coming out of what's going to be an exciting meeting.

On December 14, 2023, the FDA approved Welireg (belzutifan) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). Welireg is the first HIF-2α inhibitor therapy approved in the U.S. As an inhibitor of HIF-2α, Welireg reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. https://lnkd.in/eBJU_r4t Welireg Prescribing Information https://lnkd.in/et6V6EKU The recommended belzutifan dose is 120 mg administered orally once daily until disease progression or unacceptable toxicity. #Cancer #Oncology #HIF2α #HIF2αInbibitor #Welireg #belzutifan #RenalCellCarcinoma #RCC #Moffitt #MoffittCancerCenter Moffitt Cancer Center

Therapeutic estrogen treatment or activation of ER expression in breast cancer cases achieves excellent tumor regression.